The process of axon myelination involves various proteins including molecular chaperones. Myelin alteration is a common feature in neurological diseases due to structural and functional abnormalities of one or more myelin proteins. Genetic proteinopathies may occur either in the presence of a normal chaperoning system, which is unable to assist the defective myelin protein in its folding and migration, or due to mutations in chaperone genes, leading to functional defects in assisting myelin maturation/migration. The latter are a subgroup of genetic chaperonopathies causing demyelination. In this brief review, we describe some paradigmatic examples pertaining to the chaperonins Hsp60 (HSPD1, or HSP60, or Cpn60) and CCT (chaperonin-containing TCP-1). Our aim is to make scientists and physicians aware of the possibility and advantages of classifying patients depending on the presence or absence of a chaperonopathy. In turn, this subclassification will allow the development of novel therapeutic strategies (chaperonotherapy) by using molecular chaperones as agents or targets for treatment.

Scalia F., Marino Gammazza A., Conway De Macario E., Macario A.J.L., Cappello F. (2019). Myelin pathology: Involvement of molecular chaperones and the promise of chaperonotherapy. BRAIN SCIENCES, 9(11), 297 [10.3390/brainsci9110297].

Myelin pathology: Involvement of molecular chaperones and the promise of chaperonotherapy

Scalia F.;Marino Gammazza A.;Cappello F.
2019-01-01

Abstract

The process of axon myelination involves various proteins including molecular chaperones. Myelin alteration is a common feature in neurological diseases due to structural and functional abnormalities of one or more myelin proteins. Genetic proteinopathies may occur either in the presence of a normal chaperoning system, which is unable to assist the defective myelin protein in its folding and migration, or due to mutations in chaperone genes, leading to functional defects in assisting myelin maturation/migration. The latter are a subgroup of genetic chaperonopathies causing demyelination. In this brief review, we describe some paradigmatic examples pertaining to the chaperonins Hsp60 (HSPD1, or HSP60, or Cpn60) and CCT (chaperonin-containing TCP-1). Our aim is to make scientists and physicians aware of the possibility and advantages of classifying patients depending on the presence or absence of a chaperonopathy. In turn, this subclassification will allow the development of novel therapeutic strategies (chaperonotherapy) by using molecular chaperones as agents or targets for treatment.
https://www.mdpi.com/2076-3425/9/11/297/pdf
Scalia F., Marino Gammazza A., Conway De Macario E., Macario A.J.L., Cappello F. (2019). Myelin pathology: Involvement of molecular chaperones and the promise of chaperonotherapy. BRAIN SCIENCES, 9(11), 297 [10.3390/brainsci9110297].
File in questo prodotto:
File Dimensione Formato  
brainsci-09-00297.pdf

accesso aperto

Tipologia: Versione Editoriale
Dimensione 646.92 kB
Formato Adobe PDF
646.92 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/397365
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 3
social impact